Navigation Links
Tarsa Therapeutics Presents Positive Efficacy and Safety Data Comparing Its Oral Calcitonin to Nasal Calcitonin and Placebo in Phase III Osteoporosis Treatment Trial
Date:9/19/2011

SAN DIEGO, and PHILADELPHIA, Sept. 19, 2011 /PRNewswire/ -- Tarsa Therapeutics today reported that it presented positive safety and efficacy data from its Phase III ORACAL trial of OSTORA™, the company's oral recombinant salmon calcitonin tablet in development for the treatment of postmenopausal osteoporosis.  These data were presented at the American Society for Bone and Mineral Research 2011 Annual Meeting by ORACAL investigator Neil Binkley, MD, who is an Associate Professor of Endocrinology and Geriatrics at the University of Wisconsin School of Medicine and Public Health in Madison, Wisconsin.

The ORACAL study was a Phase III multinational, randomized, double-blind, double-dummy, placebo controlled trial of Tarsa's oral recombinant salmon calcitonin compared to placebo and to commercially available, synthetic salmon calcitonin administered by nasal spray.  The trial enrolled 565 postmenopausal women in six countries with established osteoporosis.

Earlier this year, Tarsa reported top-line efficacy and safety results from the ORACAL trial.  The data reported today show that OSTORA achieved all of the efficacy endpoints in the trial and indicate that the safety profile of OSTORA did not substantially differ from nasal calcitonin or placebo.  The majority of adverse events were mild or moderate, and OSTORA was also significantly less immunogenic than nasal calcitonin spray.  

"These are encouraging results that may be of particular relevance for the women with osteoporosis who are reluctant to take or unable to tolerate currently available treatments," said Dr. Binkley.  "Potential safety issues with current drug therapies, while rare, have led some osteoporosis patients to discontinue therapy or avoid beginning treatment.  Calcitonin has a long history of safety for postmenopausal osteoporosis treatment, and potential availability of this once-daily oral formulation could make it a useful new option
'/>"/>

SOURCE Tarsa Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Tarsa Therapeutics Reports Positive Top-Line Results From Pivotal Phase III ORACAL Trial of its Oral Calcitonin in Treatment of Postmenopausal Osteoporosis
2. Tarsa Therapeutics Completes Phase III Trial of its Oral Calcitonin for Treatment of Postmenopausal Osteoporosis and Initiates Phase II Trial in Osteoporosis Prevention
3. Silence Therapeutics Announces Issuance of Japanese Patent for Screening Therapeutics Against Key Pathway Associated with Cancer and Other Diseases
4. Echo Therapeutics Receives Registered Trademarks for Symphony® and Prelude®
5. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the UBS 2011 Global Life Sciences Conference in New York City
6. ViroPharma and Halozyme Therapeutics Announce Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze® (C1 Esterase Inhibitor [Human]) with Hyaluronidase (rHuPH20)
7. Rare Disease Therapeutics, Inc. Selects Accredo Health Group to Distribute Anascorp® for the Treatment of Centruroides Scorpion Sting Envenomation
8. Silence Therapeutics and InteRNA Technologies Sign Collaboration to Develop Novel microRNA Therapeutics
9. Nile Therapeutics to Present at Rodman & Renshaw Global Investment Conference
10. Regulus Therapeutics to Present New Advancements in microRNA Therapeutics for Treatment of Metabolic Diseases and Cancer
11. Global Sepsis Therapeutics Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... 4, 2015  Cumberland Pharmaceuticals (CPIX), today announced that ... at VirtualInvestorConferences.com on September 10, 2015. DATE: ... LINK: http://tinyurl.com/sep10pre This will ... invited to ask the company questions in real-time - ... association,s "virtual trade booth." If attendees are not able ...
(Date:9/4/2015)... September 4, 2015 Future Prospects ... Allergic Rhinitis drugs - new study ... Where is the market for allergic rhinitis drugs heading? ... Visiongain ,s new report shows you potential revenues and ... Our 326 page report provides 273 tables, ...
(Date:9/4/2015)... Research and Markets ... the "Veterinary Pharmaceutical Submissions in the EU ... to their offering. This practical two-day ... constituent parts of the application for marketing authorisation ... marketing authorisation is sought in the European Union, ...
Breaking Medicine Technology:Cumberland Pharmaceuticals to Webcast, Live, at VirtualInvestorConferences.com September 10 2Allergic Rhinitis Drugs Market Forecast 2015-2025 2Allergic Rhinitis Drugs Market Forecast 2015-2025 3Allergic Rhinitis Drugs Market Forecast 2015-2025 4Allergic Rhinitis Drugs Market Forecast 2015-2025 5Allergic Rhinitis Drugs Market Forecast 2015-2025 6Allergic Rhinitis Drugs Market Forecast 2015-2025 7Veterinary Pharmaceutical Submissions in the EU: Two day Course - London, UK - December 7-8, 2015 2
... MADISON, N.J., Aug. 12, 2011 Quest Diagnostics ... of diagnostic testing, information and services, today announced that its ... per share, payable on October 24, 2011, to shareholders of record ... About Quest Diagnostics Quest Diagnostics ...
... HeartWare International, Inc. (NASDAQ: HTWR ; ASX: ... support technologies that are revolutionizing the treatment of advanced ... scheduled to make an investor presentation at the Wedbush ... a.m. Eastern Time on Wednesday, August 17, 2011.  The ...
Cached Medicine Technology:HeartWare to Present at the Wedbush Securities 2011 Life Sciences Management Access Conference 2
(Date:9/4/2015)... (PRWEB) , ... September 04, 2015 , ... Mike Day, ... in 2007, will compete in the Ironman World Championships in Kona on October 10th. ... have incurred Traumatic Brain Injury (TBI) through combat and the cutting-edge treatments that restore ...
(Date:9/4/2015)... ... 04, 2015 , ... The conference program for the upcoming ... 9-10, 2015 at the Diplomat Resort & Spa has been announced and is ... at the top of their field and will be presenting sessions such as ...
(Date:9/4/2015)... , ... September 04, 2015 , ... ... Benker Residence in South Glastonbury, Connecticut, has been selected for the Residential Award ... significant energy efficiency and resiliency measures. Chosen from a highly competitive field of ...
(Date:9/4/2015)... ... 2015 , ... EMED Jamaica Global Ltd. (EMED), Jamaica’s premier ... into a multi-year agreement with Health City Cayman Islands. , ( http://www.healthcitycaymanislands.com ) ... healthcare, Jamaican healthcare and Health City Cayman Islands to deliver high-quality, affordable healthcare ...
(Date:9/3/2015)... ... 2015 , ... Allied Anesthesia is proud to announce a continuing partnership with ... exception. , St. Jude was recently named one of the nation’s top stroke centers ... of only 10 hospitals in the state to earn the distinction. , The ...
Breaking Medicine News(10 mins):Health News:Navy SEAL Shot 27 Times Competes in Ironman World Championship in Kona to Raise Money for Veteran's Suffering from TBI and PTSD 2Health News:Integrative Healthcare Symposium Focus On: The Microbiome Conference Program Announced 2Health News:South Glastonbury Home Selected for Award by Connecticut Green Building Council 2Health News:EMED Agreement with Health City Cayman Islands Provides for Up to 80% Savings for Patients in Need of Medical Procedures 2Health News:EMED Agreement with Health City Cayman Islands Provides for Up to 80% Savings for Patients in Need of Medical Procedures 3Health News:EMED Agreement with Health City Cayman Islands Provides for Up to 80% Savings for Patients in Need of Medical Procedures 4Health News:EMED Agreement with Health City Cayman Islands Provides for Up to 80% Savings for Patients in Need of Medical Procedures 5Health News:EMED Agreement with Health City Cayman Islands Provides for Up to 80% Savings for Patients in Need of Medical Procedures 6Health News:Allied Anesthesia Physicians Announce Partnership with St. Jude 2Health News:Allied Anesthesia Physicians Announce Partnership with St. Jude 3
... or Relenza, according to CDC , TUESDAY, Sept. 8 ... which are effective in treating the H1N1 swine flu, should ... those at high risk for complications from the disease, U.S. ... with underlying health conditions, such as asthma or diabetes, as ...
... , OAKLAND, Calif., Sept. 8 (Nasdaq: ... on August 31, 2009, the Company received a NASDAQ Staff Deficiency ... Listing Rule 5550(a)(4). This rule requires the Company to maintain ... the NASDAQ Capital Market. Subsequently on September 4, 2009, the Company ...
... MOUNTAIN VIEW, Calif., Sept. 8 VIVUS, Inc. (Nasdaq: ... and commercialization of novel therapeutic products, plans to announce the results ... on September 9th prior to market open. The announcement will ... Eastern time. , , Conference Call Information ...
... AUSTIN, Texas, Sept. 8 Organix-South, a manufacturer of ... Council,s (ABC) Adopt-an-Herb program by adopting ... will provide ABC with financial support to ensure that summaries ... ( Azadirachta indica ) are made available within ABC,s HerbMedPro ...
... , Expanding facility will provide training ... the Highbridge area of the Bronx , , ... officially open the newest addition to the non-profit agency on September ... cutting ceremony at the facility. Located at 1438 Ogden Ave., ...
... , INDIANAPOLIS, Sept. 8 WellPoint, Inc. (NYSE: ... to present at the 2009 Morgan Stanley Global Healthcare Unplugged Conference ... All interested parties are invited to listen to the webcast ... selecting the "Investor Info" link. Following the presentation, a webcast replay ...
Cached Medicine News:Health News:Antiviral Drugs Should Be Used Cautiously to Fight Flu, U.S. Says 2Health News:Antiviral Drugs Should Be Used Cautiously to Fight Flu, U.S. Says 3Health News:NASDAQ Stock Market Confirms WorldHeart's Compliance with NASDAQ Listing Rule 5550(a)(4) 2Health News:VIVUS to Host Conference Call and Webcast Discussion of Qnexa Phase 3 Results 2Health News:Organix-South Adopts Neem Through the American Botanical Council's Adopt-an-Herb Program 2Health News:Organix-South Adopts Neem Through the American Botanical Council's Adopt-an-Herb Program 3Health News:Organix-South Adopts Neem Through the American Botanical Council's Adopt-an-Herb Program 4Health News:Highbridge Community Life Center Grand Opening and Ribbon Cutting Ceremony for New Health Careers/Education Facility in the Bronx 2Health News:WellPoint Announces Appearance at Upcoming Conference 2
CCR Medical fiberoptic green system laryngoscope handles., ,OUTSTANDING PERFORMANCE, QUALITY, AND PRICING MAKE OUR FIBEROPTIC SELECTION MOST ECONOMICAL....
CCR Medical conventional laryngoscopes....
CCR Medical conventional laryngoscopes....
... LMA™ Airway., ,Launched in 1988, this ... is now standard practice in general anesthesia. ... the LMA Classic™ is a safe hands ... ,The LMA Classic™ can be used for ...
Medicine Products: